Mounjaro, a diabetes medication manufactured by Eli Lilly and Company, has seen its price reduced by 40% through a patient assistance program, lowering the cost from $1,061.40 to $611.40 per prescription. This initiative aims to make the drug more accessible to eligible patients [1].
How much does Mounjaro cost after the price cut?
Following the 40% price reduction, the out-of-pocket cost for eligible patients using Eli Lilly's patient assistance program for Mounjaro is $611.40 per prescription [1]. Previously, the drug cost $1,061.40 [1].
Who is eligible for the Mounjaro patient assistance program?
Eligibility for the Mounjaro patient assistance program is determined by specific criteria set by Eli Lilly. While the exact details of the program's eligibility requirements are not provided, such programs typically consider factors like insurance status and income level to assist patients facing financial barriers to medication access [1].
When did the Mounjaro price cut take effect?
Information regarding the specific effective date of Mounjaro's price cut is not available in the provided text.
What is Mounjaro used to treat?
Mounjaro is indicated for the treatment of type 2 diabetes. It is a dual glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide-1 (GLP-1) receptor agonist [2].
How does Mounjaro work?
Mounjaro works by activating both GIP and GLP-1 receptors. This dual action helps to improve glycemic control in individuals with type 2 diabetes [2].
Are there other diabetes medications from Eli Lilly?
Eli Lilly and Company manufactures other diabetes medications. Notably, they also produce Trulicity, a GLP-1 receptor agonist [3].
What is the difference between Mounjaro and Trulicity?
Mounjaro and Trulicity are both diabetes medications produced by Eli Lilly. The key difference lies in their mechanism of action: Mounjaro is a dual GIP and GLP-1 receptor agonist, while Trulicity is a GLP-1 receptor agonist [2, 3].
What are the potential side effects of Mounjaro?
The provided information does not detail the potential side effects of Mounjaro.
How does Mounjaro compare to other diabetes treatments?
Mounjaro's dual GIP and GLP-1 receptor agonism differentiates it from other diabetes treatments that target GLP-1 receptors alone. This dual mechanism may offer distinct therapeutic benefits for glycemic control in type 2 diabetes [2].
What are the patent and exclusivity details for Mounjaro?
Information on Mounjaro's patent and exclusivity details is not available in the provided text. DrugPatentWatch.com tracks such information for various pharmaceuticals.
What is the outlook for Mounjaro's market exclusivity?
Details regarding Mounjaro's market exclusivity timeline are not present in the provided information.
What are the financial implications of Mounjaro's price reduction?
The 40% price cut on Mounjaro, bringing the cost down to $611.40 per prescription for eligible patients, is intended to improve affordability. This could potentially increase patient adherence and reduce the financial burden associated with managing type 2 diabetes for those who qualify for the assistance program [1].
Sources:
1. https://www.drugpatentwatch.com/blog/mounjaro-price-cut-40-percent-patient-assistance-program
2. https://www.drugpatentwatch.com/drugs/mounjaro
3. https://www.drugpatentwatch.com/drugs/trulicity